FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to leprology, and can be used particularly for the detection of specific liver disease in the leprosy patients. Blood serum of the leprosy patients is analysed to determine the level of US-M.leprae and DIS-BSA leprosy mycobacteria antigen antibodies, and also the concentration of alpha-1-antitrypsin. If observing the level of antibodies to two antigens increased as compared to a norm and the concentration of alpha-1-antitrypsin increased higher than 346.7 mg/dl, liver disease is detected in the leprosy patients.
EFFECT: method provides higher accuracy.
4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF LEPROSY DIAGNOSIS | 1996 |
|
RU2124730C1 |
| METHOD OF ESTIMATION OF LEPROSY RELAPSE RISK GROUP | 1993 |
|
RU2082979C1 |
| METHOD OF IDENTIFICATION OF MYCOBACTERIUM LEPRAE IN PATIENTS WITH DISEASE REGRESSION | 1997 |
|
RU2137137C1 |
| METHOD FOR Mycobacterium leprae ANTIBODY TEST | 2012 |
|
RU2500423C1 |
| METHOD FOR Mycobacterium leprae ANTIBODY TEST | 2012 |
|
RU2501022C2 |
| METHOD FOR DIAGNOSING LEPROSIS | 2000 |
|
RU2171689C1 |
| METHOD OF DETECTING ANTIBODIES TO MYCOBACTERIUM LEPRAE ON SOLID CARRIER | 2010 |
|
RU2468371C2 |
| STRAIN OF BACTERIUM MYCOBACTERIUM AVIUM USED FOR LEPROSY DIAGNOSIS | 1994 |
|
RU2080377C1 |
| METHOD FOR DETERMINING LEPROSY FORM | 2004 |
|
RU2279087C2 |
| METHOD FOR PREDICTION OF RECURRENCE RISK IN LEPROSY PATIENTS | 2008 |
|
RU2373529C1 |
